Ocumetics Reaches 12-Month Clinical Milestone

Ocumetics Technology Corp. has reached a significant milestone in its clinical development program for the Ocumetics Lens, an accommodating intraocular lens designed to provide a more natural range of vision. The company's first-in-human Group One patients have completed their 12-month follow-up examinations, marking an important point in the clinical development process.

According to Dean Burns, President and CEO of Ocumetics Technology Corp., "When you are developing a technology at this stage, every clinical milestone matters. But some milestones matter for reasons that go beyond the numbers." Burns continued, "At one month, we saw evidence that patients were beginning to achieve meaningful functional vision. At three months, those early results were continuing to develop and that we were meeting important internal clinical benchmarks. At six months, patients began describing how their improved vision was affecting their everyday lives, including the ability to read more easily, watch television, recognize family members, and participate in everyday activities with greater visual independence."

At approximately one month following surgery, all patients achieved distance vision of 20/40 or better. This represented a significant improvement in functional vision for patients who entered the study with significant visual impairment, providing an early indication that the Ocumetics Lens could be safely implanted and had the potential to deliver meaningful visual benefits.

By three months, Group One patient results met or exceeded the company's predefined internal benchmarks for safety, lens delivery, and foundational distance vision performance. The continued improvement observed in Group One patients supported the company's decision to advance its clinical development program.

At six months following surgery, patients continued to demonstrate encouraging visual outcomes while the safety profile remained encouraging. Importantly, patients began describing how improved vision was affecting their everyday lives, including the ability to read more easily, watch television, recognize family members, and participate in everyday activities with greater visual independence. In one case, a previously legally blind patient achieved vision that qualified them to drive.

For Ocumetics, these experiences highlight the potential impact of its lens technology beyond an eye-chart measurement. Burns stated, "Our objective has never been simply to create another intraocular lens. We are pursuing a technology designed around a fundamentally different vision of what an intraocular lens could ultimately provide: a more natural range of vision and, potentially, greater visual freedom with no side effects."

The company is now preparing to advance to the next group of patients. Unlike Group One, which focused solely on safety, the primary and secondary purposes of the Group Two surgeries are to study the safety, distance, and near vision performance of the Ocumetics Lens.

Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.